S&P Pharma Dose

S&P Global Ratings

Hosted by Arthur Wong, Ji Liu, and other editors and analysts, the S&P Pharma Dose podcast from S&P Global Ratings discusses all things pharma from a credit perspective.

  1. 21.09.2020

    What Bausch RemainCo's Credit Quality Post-Spinoff Could Look Like

    In this episode, Ji Liu, primary analyst for Bausch Health, discusses a number of investor questions after Bausch announced its intention to spin off its eye health business unit, specifically regarding its capital structure, key business strengths, key business weaknesses, and other concerns.

    7 min.

  2. 05.08.2020

    Regeneron Pharmaceuticals: Steady Growth vs. Heavy Product Concentration

    S&P Global Ratings' senior pharma analyst, Ji Liu, discusses the puts and takes for our new Regeneron Pharmaceuticals ratings.

    8 min.

  3. 11.02.2020

    Episode 34: More Color on PPD's Rating After IPO

    In this episode of S&P Pharma Dose, senior healthcare analyst Ji Liu discusses his view on Pharmaceutical Product Development LLC (PPD) after its recent IPO on Feb. 5, 2020.

    7 min.

  4. 21.01.2020

    Episode 33: Pharmacy Benefit Manager Industry In 2020: Less Regulatory Overhang, Expect More Consolidations

    In this episode of S&P Pharma Dose, Ji Liu, Deep Banerjee and Andy Sookram discuss the annual PBM outlook report along with their view on high-profile issuers UnitedHealth, Cigna, CVS and Rite Aid.

    10 min.

  5. 01.08.2019

    Episode 32: Pfizer Finds Home For Upjohn, Though Lessened Diversity Results In Lower Rating

    The S&P Pharma Guy, Arthur Wong, shares S&P Global's thoughts on Pfizer Inc.'s announcement it was spinning off Upjohn, home to legacy products Lipitor, Viagra, and Lyrica. Pfizer remains a pharma giant and leading player in the industry. However, the lessened diversity will result in a lower rating.

    9 min.

  6. 07.03.2019

    Episode 31: Thoughts On Pharma's Washington Grilling

    S&P Global's pharmaceutical themed podcast show returns with some quick thoughts on the pharma industry's testimony at a congressional hearing on Capitol Hill. A comprehensive list of challenges/criticisms of the industry, but where were the suggested solutions? Noise level on pharma pricing is only going to increase as we near presidential election.

    12 min.

  7. 03.08.2018

    Episode 30: Rebates And Pharma Supply Chain

    Healthcare analysts Tulip Lim and Ji Liu drop in on the S&P Pharma Guy, Arthur Wong, to talk how HHS's proposal to ban rebating from the Medicare market. What's the impact on the ratings of the pharma supply chain players?

    10 min.

  8. 11.07.2018

    Episode 29: Just When You Thought It Was Safe to Go Back In the Water - Amazon Buys PillPack

    Managing Director, Bob Schulz from S&P Global's retail team and Director, Tulip Lim, of the healthcare team drop in on the show to share thoughts on Amazon's recent no-longer-a-rumor move into the pharmacy space. What does it mean for the pharmaceutical supply chain? How concerned should we be from a ratings standpoint for the pharmacy chains and pharma wholesalers?

    17 min.
Se alle (35)

Om

Hosted by Arthur Wong, Ji Liu, and other editors and analysts, the S&P Pharma Dose podcast from S&P Global Ratings discusses all things pharma from a credit perspective.

Oplysninger

  • Skaber
    S&P Global Ratings
  • Aktive år
    2 t
  • Episoder
    35
  • Vurdering
    Ikke anstødeligt
  • Copyright
    © Copyright 2021 S&P Global. All rights reserved. https://www.spglobal.com/
  • Websted for serie
    S&P Pharma Dose